全文获取类型
收费全文 | 1574549篇 |
免费 | 113104篇 |
国内免费 | 4646篇 |
专业分类
耳鼻咽喉 | 20422篇 |
儿科学 | 52011篇 |
妇产科学 | 45032篇 |
基础医学 | 233184篇 |
口腔科学 | 42291篇 |
临床医学 | 148901篇 |
内科学 | 301817篇 |
皮肤病学 | 31664篇 |
神经病学 | 128602篇 |
特种医学 | 57632篇 |
外国民族医学 | 407篇 |
外科学 | 222410篇 |
综合类 | 35500篇 |
现状与发展 | 2篇 |
一般理论 | 603篇 |
预防医学 | 130445篇 |
眼科学 | 34878篇 |
药学 | 115437篇 |
6篇 | |
中国医学 | 3830篇 |
肿瘤学 | 87225篇 |
出版年
2021年 | 12618篇 |
2019年 | 13336篇 |
2018年 | 19045篇 |
2017年 | 14318篇 |
2016年 | 15653篇 |
2015年 | 17880篇 |
2014年 | 24390篇 |
2013年 | 37853篇 |
2012年 | 51229篇 |
2011年 | 54253篇 |
2010年 | 31934篇 |
2009年 | 29334篇 |
2008年 | 49584篇 |
2007年 | 52599篇 |
2006年 | 52622篇 |
2005年 | 50727篇 |
2004年 | 48478篇 |
2003年 | 46052篇 |
2002年 | 44475篇 |
2001年 | 71131篇 |
2000年 | 73006篇 |
1999年 | 61097篇 |
1998年 | 17009篇 |
1997年 | 15510篇 |
1996年 | 15212篇 |
1995年 | 14491篇 |
1994年 | 13464篇 |
1993年 | 12686篇 |
1992年 | 48105篇 |
1991年 | 47391篇 |
1990年 | 45939篇 |
1989年 | 43873篇 |
1988年 | 40478篇 |
1987年 | 39351篇 |
1986年 | 37532篇 |
1985年 | 35841篇 |
1984年 | 26813篇 |
1983年 | 22899篇 |
1982年 | 13788篇 |
1979年 | 24489篇 |
1978年 | 17535篇 |
1977年 | 14367篇 |
1976年 | 13977篇 |
1975年 | 14523篇 |
1974年 | 17606篇 |
1973年 | 17276篇 |
1972年 | 16014篇 |
1971年 | 14945篇 |
1970年 | 13888篇 |
1969年 | 12648篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
31.
Sundaram Kavin Piuzzi Nicolas S. Patterson Brendan M. Stearns Kim L. Krebs Viktor E. Mont Michael A. 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):447-453
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate... 相似文献
32.
33.
34.
Annals of Nuclear Medicine - The Response Evaluation Criteria In Solid Tumors (RECIST) is the most used radiological method for evaluating response after peptide receptor radionuclide therapy... 相似文献
35.
36.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
37.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
38.
In 1963, Goffman argued that forming a group based on shared stigma may provide benefits. However, there is no empirical research on whether perception that a separate, unique, coherent group exists (i.e., group entitativity) influences coping, such as educating others or secrecy, for the stigmatized individual or his or her spouse. Further, little is known about how spouses influence each other in terms of promoting the education of others about a stigmatizing condition, especially when it comes to the role of believing that stigma-based groups, to which they may both belong, exist. This study provides a step toward bridging this gap in the research by applying the label management model in efforts to understand coping for couples in which one spouse is diagnosed with genetic mutations leading to alpha-1 antitrypsin deficiency (AATD). This study included 50 married couples in which one spouse is diagnosed with genetic mutations leading to alpha-1 antitrypsin deficiency (AATD). We found that group entitativity related to those with AATD counterbalanced the influence of genetic stigma on spouses’ intentions to keep the diagnosis secret or to educate others about it. Intrapersonal and interpersonal influences appeared among spouses. Attention is needed on the power of creating groups for stigmatized persons and their relatives. Indeed, people live within a dynamic world of group entities, and multiple social identities including spousal and familial. While attention has been paid to the diffusion of stigmas to loved ones, less has been paid to the uplift of group entities for them. 相似文献
39.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study 下载免费PDF全文
40.